Tesamorelin is a synthetic peptide that is used to treat excess abdominal fat in people with HIV-associated lipodystrophy. It works by stimulating the production of growth hormone-releasing hormone (GHRH), which in turn stimulates the production of growth hormone (GH) in the pituitary gland.
GH is a hormone that is essential for growth and development, but it also plays a role in metabolism and body composition. In people with HIV-associated lipodystrophy, GH levels are often low, which can lead to an accumulation of abdominal fat.
Tesamorelin helps to increase GH levels, which can lead to a reduction in abdominal fat. In clinical trials, tesamorelin has been shown to be effective at reducing abdominal fat in people with HIV-associated lipodystrophy.
One of the advantages of tesamorelin is that it is administered by injection, which makes it easy to use. It is typically given once a day, and the injection can be self-administered at home.
However, tesamorelin is not without its risks. It can cause side effects such as joint pain, muscle pain, and swelling at the injection site. It can also increase the risk of diabetes and other metabolic disorders.
Overall, tesamorelin is a promising treatment for excess abdominal fat in people with HIV-associated lipodystrophy. It has been shown to be effective at reducing abdominal fat, and it is easy to use. However, it is important to weigh the potential benefits against the risks before starting treatment.